Product Code: RP-ID-10352398 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10352398
Market Overview:
One-Step ELISA Market Analysis by Application (Hospitals & Clinics, Diagnostic Centers, Pharmaceutical Companies, and Research Centers); by Sample Type (Tissue Lysate, Plasma, & Serum, and Others); and by Target Molecule (Insulin, Albumin, IgG, TNF Alpha, Lysozyme, IL-6, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Global One-Step ELISA Market Size, Forecast, and Trend Highlights Over 2022 - 2031
The global one-step ELISA market is estimated to garner a revenue of approximately USD 9.0 billion by the end of 2031 by growing at a CAGR of ~4% over the forecast period, i.e., 2022 – 2031. Further, the market generated a revenue of approximately USD 5.0 billion in the year 2021. The growth of the market can majorly be attributed to the rise in the prevalence of chronic diseases across the globe. For instance, according to the data published by World Health Organization (WHO) in 2021, non-communicable diseases result in approximately 41 million people deaths each year, accounting for 71 percent of the deaths worldwide.
GET A SAMPLE COPY OF THIS REPORT
ELISA which stands for enzyme-linked immunosorbent assay, is a laboratory test that is commonly used to detect antibodies in the blood. An antibody is a protein that the body's immune system produces when it detects harmful substances known as antigens. Moreover, the ELISA test, is frequently preferred by medical professionals considering its accuracy in comparison to other techniques. With the recent development in ELISA technique, the one-step ELISA method has become more popular owing to its improved detection sensitivity and reduction in operating time. The four main types of ELISAs, depending upon the different methods used for antigen-antibody binding, are direct, indirect, sandwich, and competitive, which give rise to a wide range of applications such as clinical, forensic, and food research. Some of the applications of the ELISA test include cancer screening, drug and pregnancy testing, detection of platelate antibodies, food allergens, and detection of viruses such as HIV, West Nile Virus, NDV, SARSCoV2 (COVID19), and others. For instance, the total number of COVID-19 tests performed in the United States by June 2022 is estimated to be 911 million, up from 470 million in 2021. Therefore, detection of viruses such as COVID-19 at an earlier stage is expected to boost the growth of the market.
Global One-Step ELISA Market: Growth Drivers and Challenges
Growth Drivers
-
Surge in the Geriatric Population, Worldwide – Older people experiences a significant amount of risk of developing severe illness if they contract a disease as a result of physiological changes associated with ageing and potential underlying health conditions. According to the World Health Organization (WHO) the percentage of the world population aged more than 60 years is expected to surge from 12 percent to 22 percent between 2015 and 2050.
-
Rise in the Health Expenditure Across the Globe– According to the Centers for Medicare & Medicaid Services, national health spending in the United States is expected to rise at an average rate of 5.5 percent annually and is expected to reach approximately USD 6.0 trillion by the end of the year 2027.
-
Growing Disease Awareness Among People– Early treatment is critical for preventing morbidity and mortality, thus highlighting the significance of early diagnosis. Different initiatives are being taken by governmental organizations across the globe to create awareness among people about growing diseases for early detection, which is anticipated to spur the growth of the market. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), an estimated 1.5 million people worldwide contracted HIV in 2020, representing a 31 percent decrease in new infections since 2010 owing to the increased disease awareness and early diagnosis.
-
Increasing Demand for Clinical Laboratories and Diagnostic Centers- There has been an increase in the demand for clinical laboratories and diagnostic centers across the globe, especially after the COVID-19 outbreak, which is anticipated to drive the growth of the global one-step ELISA market. According to the U.S. Centers for Disease Control and Prevention (CDC), there were around 260000 CLIA-certified laboratories in the United States which represented the cornerstone of diagnostic medicine in today’s era. The statistics also stated that 14 Billion laboratory tests were ordered each year in the nation.
Challenges
-
Difficulty in Obtaining Regulatory Approval for the ELISA Test
-
False Results (False Positive or False Negative) are Often Observed
-
High Cost of ELISA Supplies
The global one-step ELISA market is segmented and analyzed for demand and supply by application into hospitals & clinics, diagnostic centers, pharmaceutical companies, and research centers. Out of which, the pharmaceutical companies are anticipated to hold the largest share over the forecast period in the market owing to the growth of the pharmaceutical industry and its rise in expenditure on research and development. According to the International Federation of Pharmaceutical Manufacturers and Associations, the research-based biopharmaceutical industry has spent approximately USD 179 billion on biopharmaceutical R&D globally in 2018.
Global One-Step ELISA Market Regional Synopsis
Regionally, the global one-step ELISA market is studied into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region. Amongst these, the market in the North America region is projected to hold the largest market share by the end of 2031. This can be attributed to the growing awareness related to early detection of diseases among the population, the rise in the geriatric population, and an increase in health care expenditure. According to the World Bank, the current health expenditure in North America has increased from 14.15 percent of the GDP in 2005 to 16.32 percent of the GDP in 2019.
Current Health Expenditure (% of GDP), 2000-2019, North America
Source: The World Bank
Market Segmentation
Our in-depth analysis of the global one-step ELISA market includes the following segments:
|
By Application |
|
|
By Sample Type |
|
|
By Target Molecule |
|
Key Companies Dominating the Global One-Step ELISA Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global one-step ELISA market that are included in our report are Boster Biological Technology, PerkinElmer Inc., AnaSpec Inc., Abcam plc., InBios International, Inc., Immunodiagnostic Systems Holdings PLC, DIALAB GmbH, Therma Fisher Scientific, Enzo Life Sciences, Inc., Abnova Corporation, and others.
Global One-Step ELISA Market: Latest Developments
-
October, 2021: Abcam plc., announced the acquisition of BioVision in order to expand its immunoassay kit capability and capacity in Eugene, OR.
-
July, 2021: PerkinElmer Inc., announced the agreement to acquire BioLegend for nearly USD 5.25 billion subject to certain conditions. The purpose of the acquisition is to bring innovative cultures and technology together to provide seamless solutions.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Boster Biological Technology
- PerkinElmer Inc.
- AnaSpec Inc.
- Abcam plc.
- InBios International Inc.
- Immunodiagnostic Systems Holdings PLC
- DIALAB GmbH
- Therma Fisher Scientific
- Enzo Life Sciences Inc.
- Abnova Corporation
Related Reports
Proof of Quality & Reliability
